-5%
Linagliptin functions as a DPP-4 inhibitor, preventing the breakdown of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones regulate glucose homeostasis by increasing insulin secretion and reducing glucagon levels in a glucose-dependent manner. GLP-1 also decreases hepatic glucose production.
Empagliflozin, an SGLT2 inhibitor, blocks glucose reabsorption in the kidneys, thereby lowering the renal glucose threshold and promoting glucose excretion through urine. This mechanism helps reduce blood sugar levels.
Limpa is prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.